MedTrace Logo

REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

NCT02366026 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2016-02-23

No results posted yet for this study

Summary

The primary objective is to compare \& evaluate between the treatment groups the changes in decline/reduction of HIV viral load changes in the Remune + Amplivax group vs the Amplivax placebo groups. Additional objectives include changes in WBC White Blood Cell counts \& CD4+ \& CD8+ T cell counts along with increased HIV immunity.

Conditions

Interventions

BIOLOGICAL

IR103

REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax

Sponsors & Collaborators

  • Immune Response BioPharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Bartholomew, PhD · Immune Response BioPharma, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02366026 on ClinicalTrials.gov